Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study).

Matteo BassettiAntonio VenaDaniele Roberto GiacobbeMarco FalconeGiusy TiseoMaddalena GiannellaRenato PascaleMarianna MeschiariMargherita DigaetanoAlessandra OlivaCristina RovelliNovella CarannanteAngela Raffaella LositoSergio CarbonaraMichele Fabiano MarianiAntonio MastroianniGioacchino AngaranoMario TumbarelloCarlo TasciniPaolo GrossiClaudio Maria MastroianniCristina MussiniPierluigi VialeFrancesco MenichettiClaudio ViscoliAlessandro Russonull null

Published in: Open forum infectious diseases (2020)

Data show that C/T could be a valid option in empiric and/or targeted therapy in patients with severe infections caused by ESBL-producing Enterobacterales. Clinicians should be aware of the risk of clinical failure with standard-dose C/T therapy in septic patients receiving CRRT.

Keyphrases

escherichia coli
early onset
klebsiella pneumoniae
gram negative
cross sectional
palliative care
electronic health record
multidrug resistant
big data
clinical trial
machine learning
bone marrow
replacement therapy
cell therapy